{"id":56972,"date":"2024-02-27T17:16:42","date_gmt":"2024-02-27T17:16:42","guid":{"rendered":"https:\/\/medsname.com\/ezedoc\/"},"modified":"2026-08-28T11:51:18","modified_gmt":"2026-08-28T11:51:18","slug":"ezedoc","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/ezedoc\/","title":{"rendered":"Ezedoc"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 0 0 24px 0; border-radius: 4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin: 0 0 8px 0; font-size: 16px; font-weight: bold;\">\u26a1 Quick Answer \u2014 What is Ezedoc?<\/h3>\n<p style=\"margin: 0;\"><strong>Ezedoc<\/strong> con\u021bine <strong>ezetimibe<\/strong> (10 mg), un <strong>inhibitor al absorb\u021biei de colesterol<\/strong> care blocheaz\u0103 transportorul NPC1L1 \u00een intestinul sub\u021bire. Este <strong>go-to add-on therapy when a statin alone doesn\u2019t get LDL to target<\/strong>. On its own, ezetimibe lowers LDL-C by about 17\u201322%. Added to a statin, it produces an additional ~20\u201325% LDL reduction, totaling a 55\u201360% fall \u2014 equivalent to doubling the statin dose without the dose-related muscle or liver side effects. The <strong>(18.144 pacien\u021bi post-ACS) a demonstrat c\u0103 ad\u0103ugarea ezetimibului la simvastatin reduce \u00een continuare evenimentele cardiovasculare. Doz\u0103: 10 mg o dat\u0103 pe zi, \u00een orice moment, cu sau f\u0103r\u0103 m\u00e2ncare. \u00cen general foarte bine tolerat \u2014 tulbur\u0103ri gastrointestinale u\u0219oare, mialgii ocazionale, eleva\u021bii rare ale transaminazelor. Evita\u021bi \u00een insuficien\u021b\u0103 hepatic\u0103 sever\u0103.<\/strong> trial (18,144 patients post-ACS) proved that adding ezetimibe to simvastatin further reduces cardiovascular events. Dose: 10\u00a0mg once daily, any time, with or without food. Generally very well-tolerated \u2014 mild GI upset, occasional myalgia, rare transaminase elevation. Avoid in severe hepatic impairment.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate \u00een \u00eentreaga lume \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 nume de medicament pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesator reglementat (descrierile de pe extrasul de cont includ un procesator de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau nume de medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este acoperit\u0103 de Politica noastr\u0103 de Asigurare pentru Retrimitere.<\/p>\n<h2 class=\"wp-block-heading\">Ezedoc este un medicament hipolipemiant oral care con\u021bine<\/h2>\n<p>Ezedoc este un medicament hipolipemiant oral care con\u021bine <strong>ezetimibe<\/strong> (10 mg), fabricat de un produc\u0103tor certificat WHO-GMP. Furnizat \u00een cutii de 30, 60, 90 sau 180 de comprimate. Ezetimibe este primul \u0219i singurul medicament din clasa <strong>inhibitor al absorb\u021biei de colesterol<\/strong> Zetia \/ Ezetrol <strong>(Merck, 2002).<\/strong> Ezetimibul este un pilon al managementului lipidic de linia a doua \u2014 prima alegere atunci c\u00e2nd ave\u021bi nevoie de o reducere mai mare a LDL dec\u00e2t ofer\u0103 o doz\u0103 tolerat\u0103 de statin sau c\u00e2nd un pacient nu tolereaz\u0103 doze mai mari de statine. Este, de asemenea, cel mai frecvent partener \u00een combina\u021bii cu doz\u0103 fix\u0103 (simvastatin\/ezetimib = Inegy\/Vytorin; rosuvastatin\/ezetimib = diverse).<\/p>\n<p>Ezetimibe is a mainstay of second-line lipid management \u2014 the first choice when you need more LDL reduction than a tolerated statin dose provides, or when a patient cannot tolerate higher statin doses. It is also the most common partner in fixed-dose combinations (simvastatin\/ezetimibe = Inegy\/Vytorin; rosuvastatin\/ezetimibe = various).<\/p>\n<h2 class=\"wp-block-heading\">\u2014 ca terapie de completare la un statin atunci c\u00e2nd LDL nu atinge \u021binta la doza maxim\u0103 tolerat\u0103 de statin<\/h2>\n<ul>\n<li><strong>Hipercolesterolemie primar\u0103<\/strong> \u2014 as add-on to a statin when LDL is not at goal on the maximum tolerated statin dose<\/li>\n<li><strong>Intoleran\u021b\u0103 la statine<\/strong> \u2014 as monotherapy or with a very low statin dose when a full statin dose causes muscle or liver problems<\/li>\n<li><strong>Hipercolesterolemie familial\u0103<\/strong> (heterozygous and homozygous) \u2014 in combination with statin<\/li>\n<li><strong>Preven\u021bie secundar\u0103 dup\u0103 sindromul coronarian acut<\/strong> \u2014 add to statin to further reduce CV events (IMPROVE-IT trial)<\/li>\n<li><strong>Sitosterolemie<\/strong> \u2014 a rare genetic condition where ezetimibe is disease-modifying<\/li>\n<\/ul>\n<p>Ezetimibe is weak as a monotherapy (~17% LDL reduction) compared to a statin (~30\u201360%); it is most powerful as an add-on.<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Ezedoc?<\/h2>\n<p>Ezetimiba inhib\u0103 selectiv <strong>transportorul Niemann-Pick C1-Like 1 (NPC1L1)<\/strong> de pe enterocitele din intestinul sub\u021bire proximal. NPC1L1 este responsabil pentru absorb\u021bia colesterolului alimentar \u0219i biliar din lumenul intestinal \u00een enterocit.<\/p>\n<p>Cu NPC1L1 blocat:<\/p>\n<ul>\n<li><strong>Absorb\u021bia intestinal\u0103 a colesterolului scade cu ~54%<\/strong><\/li>\n<li><strong>Depozitele hepatice de colesterol scad<\/strong> deoarece mai pu\u021bin colesterol ajunge la ficat<\/li>\n<li><strong>receptorii LDL sunt regla\u021bi \u00een sus<\/strong> on hepatocytes \u2014 the liver pulls more LDL out of the blood<\/li>\n<li><strong>Plasma LDL-C falls by 17\u201322%<\/strong> ca monoterapie; p\u00e2n\u0103 la 25% suplimentar atunci c\u00e2nd este combinat cu un statin<\/li>\n<li>activitatea HMG-CoA reductazei (\u021binta statinelor) este neschimbat\u0103<\/li>\n<\/ul>\n<p>Deoarece ezetimiba \u0219i statinele ac\u021bioneaz\u0103 asupra <strong>c\u0103ilor complementare<\/strong> (absorption vs synthesis), their effects are additive. Statins reduce LDL synthesis; ezetimibe reduces LDL absorption\/input. Together they drop LDL more than either can alone, without adding to each other\u2019s side-effect profile.<\/p>\n<p>Date de rezultat: <strong>Studiul IMPROVE-IT<\/strong> (2015) a demonstrat c\u0103 ad\u0103ugarea ezetimibe la simvastatin la pacien\u021bii post-SCA a redus punctul final CV compozit cu 6,4% (NNT 50 pe 7 ani), confirm\u00e2nd c\u0103 sc\u0103derea LDL se traduce \u00eentr-o reducere real\u0103 a evenimentelor.<\/p>\n<h2 class=\"wp-block-heading\">Doza \u0219i administrare<\/h2>\n<p><strong>Doza standard:<\/strong> 10\u00a0mg once daily at any time of day, with or without food.<\/p>\n<ul>\n<li>Lua\u021bi la aceea\u0219i or\u0103 pentru respectarea tratamentului.<\/li>\n<li>Can be taken at the same time as a statin or spaced out \u2014 no timing interaction.<\/li>\n<li>Miss a dose \u2014 take it as soon as you remember unless close to the next; do not double up.<\/li>\n<li>Nu este necesar\u0103 ajustarea dozei pentru insuficien\u021b\u0103 renal\u0103 sau insuficien\u021b\u0103 hepatic\u0103 u\u0219oar\u0103 p\u00e2n\u0103 la moderat\u0103.<\/li>\n<li>Monitor lipid panel and ALT at baseline and 6\u20138 weeks after starting. Check CK only if symptoms.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p>Ezetimibe este unul dintre cele mai bine tolerate medicamente hipolipemiante. Evenimentele adverse sunt aproape de ratele placebo \u00een studii.<\/p>\n<p><strong>Frecvente (&lt; 5%):<\/strong><\/p>\n<ul>\n<li>Diaree u\u0219oar\u0103, flatulen\u021b\u0103<\/li>\n<li>Infec\u021bie ale tractului respirator superior, sinuzit\u0103<\/li>\n<li>Oboseal\u0103<\/li>\n<li>Artralgie<\/li>\n<\/ul>\n<p><strong>Mai pu\u021bin frecvente:<\/strong><\/p>\n<ul>\n<li>Transaminase elevation \u2014 usually small; more common when combined with a statin<\/li>\n<li>Muscle pain, myalgia, myopathy \u2014 rare; primarily when combined with statin<\/li>\n<li>Hipersensibilitate, angioedem, erup\u021bie cutanat\u0103<\/li>\n<li>Pancreatitis \u2014 very rare<\/li>\n<li>Cholelithiasis \u2014 very rare<\/li>\n<li>Thrombocytopenia \u2014 very rare<\/li>\n<li>Rhabdomyolysis \u2014 exceedingly rare, almost always in combination with a statin<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Ciclosporin\u0103<\/strong> \u2014 significantly raises ezetimibe levels (and vice versa). Monitor cyclosporine levels; some guidance suggests avoiding.<\/li>\n<li><strong>Sequestran\u021bi de acizi biliari<\/strong> (cholestyramine, colestipol) \u2014 reduce ezetimibe absorption; take ezetimibe at least 2 hours before or 4 hours after.<\/li>\n<li><strong>Warfarin<\/strong> \u2014 occasional INR change reported; monitor when starting.<\/li>\n<li><strong>Statine<\/strong> \u2014 no adverse PK interaction; this combination is the therapeutic mainstay.<\/li>\n<li><strong>Fibrate<\/strong> \u2014 fenofibrate\/ezetimibe combination is safe; gemfibrozil raises ezetimibe levels and is generally avoided.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Cine nu ar trebui s\u0103 ia Ezedoc?<\/h2>\n<ul>\n<li>Insuficien\u021b\u0103 hepatic\u0103 moderat\u0103 p\u00e2n\u0103 la sever\u0103 (c\u00e2nd este combinat\u0103 cu un statin)<\/li>\n<li>Active liver disease or persistent transaminase elevation &gt; 3\u00d7 ULN<\/li>\n<li>Sarcin\u0103 (c\u00e2nd este combinat cu un statin)<\/li>\n<li>Al\u0103ptare<\/li>\n<li>Copii &lt; 10 ani (date insuficiente)<\/li>\n<li>Hipersensibilitate cunoscut\u0103 la ezetimib\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>Store Ezedoc below 25\u00b0C in a dry place, in the original blister. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Pot lua Ezedoc \u00een locul unui statin?<\/h3>\n<p>Usually no. As monotherapy, ezetimibe lowers LDL by only ~17% \u2014 much less than a statin (30\u201360%). It is appropriate as monotherapy only for patients who cannot tolerate any statin at any dose. For most people, the best lipid-lowering strategy is statin first, ezetimibe added if LDL is still above target.<\/p>\n<h3 class=\"wp-block-heading\">Cum se compar\u0103 Ezedoc cu dublarea dozei de statin?<\/h3>\n<p>Doubling a statin dose typically adds ~6% LDL reduction (the statin \u201crule of 6\u201d). Adding ezetimibe adds ~20\u201325% LDL reduction. <strong>Adding ezetimibe is 3\u20134\u00d7 more effective<\/strong> dec\u00e2t dublarea statinului, f\u0103r\u0103 cre\u0219terea simptomelor musculare legate de doz\u0103. Acesta este motivul pentru care ghidurile moderne recomand\u0103 combina\u021bia statin + ezetimib\u0103 \u00een loc de cre\u0219terea statinului la doza maxim\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Reduce Ezedoc infarctul miocardic \u0219i accidentul vascular cerebral?<\/h3>\n<p>Yes \u2014 the IMPROVE-IT trial (18,144 post-ACS patients) showed adding ezetimibe to simvastatin reduced the composite endpoint of CV death, MI, unstable angina, revascularisation, or stroke by 6.4% over 7 years. This is the landmark evidence that LDL reduction beyond statins alone still translates into real cardiovascular benefit.<\/p>\n<h3 class=\"wp-block-heading\">C\u00e2nd ar trebui s\u0103 iau Ezedoc?<\/h3>\n<p>Any time of day is fine. Unlike simvastatin (evening preferred), ezetimibe timing is not dose-dependent \u2014 pick a time you will remember consistently. Many patients take it at the same time as their statin.<\/p>\n<h3 class=\"wp-block-heading\">Cauzeaz\u0103 Ezedoc dureri musculare ca statinele?<\/h3>\n<p>Rar. Monoterapia cu ezetimib\u0103 prezint\u0103 efecte secundare musculare la nivel de placebo. Atunci c\u00e2nd este combinat\u0103 cu o statin\u0103, nu cre\u0219te semnificativ simptomele musculare legate de statin\u0103 \u00een compara\u021bie cu statina singur\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Unde pot cump\u0103ra Ezedoc online?<\/h3>\n<p>Pute\u021bi comanda Ezedoc (10 mg) de la MedsBase \u00een cutii de 30, 60, 90 sau 180 de comprimate. Livr\u0103m \u00een \u00eentreaga lume cu ambalaj discret \u0219i stocuri autentice de la produc\u0103tori certifica\u021bi WHO-GMP.<\/p>\n<h2 class=\"wp-block-heading\">Medicamente \u00eenrudite pentru colesterol<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lipvas\/\">Lipvas \u2014 Atorvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/crestor\/\">Crestor \u2014 Rosuvastatin 5\/10\/20 mg (AstraZeneca)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/rosuline\/\">Rosuline \u2014 Rosuvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/atorvatin\/\">Atorvatin \u2014 Atorvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/pivasta\/\">Pivasta \u2014 Pitavastatin (interaction-clean)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lipicard\/\">Lipicard \u2014 Fenofibrate (for triglycerides)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/high-cholesterol-treatments\/\"><strong>R\u0103sfoi\u021bi toate medicamentele pentru colesterol ridicat<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background: #fff3f3; border-left: 4px solid #d9534f; padding: 16px 20px; margin: 24px 0; border-radius: 4px;\"><strong>\u2695 Medical Disclaimer.<\/strong> Aceast\u0103 pagin\u0103 are doar scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical al unui profesionist calificat din domeniul s\u0103n\u0103t\u0103\u021bii. Dureri musculare neexplicate, g\u0103lbirea pielii sau a ochilor sau dureri abdominale severe necesit\u0103 evaluare medical\u0103 imediat\u0103.<\/div>\n<h3 class=\"wp-block-heading\">De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Ezedoc este furnizat printr-un produc\u0103tor certificat WHO-GMP cu documenta\u021bie COA complet\u0103. Livr\u0103m \u00een \u00eentreaga lume \u00een ambalaje simple \u0219i discrete, iar fiecare comand\u0103 este acoperit\u0103 de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>. Your statement descriptor when paying by card shows the regulated payment processor (a regulated card-payment processor), never \u201cMedsBase\u201d or any medication name.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/bencid\/\">Bencid<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tiova-rotacaps\/\">Tiova Rotacaps<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/serobid-rotacaps\/\">Serobid Rotacaps<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/headset\/\">Casc\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xafinact\/\">Xafinact<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Reduceaz\u0103 Nivelul Colesterolului<br \/>\n\u2705 Reduce riscul de boli cardiace<br \/>\n\u2705 Previne Ateroscleroza<br \/>\n\u2705 Prescris de Medici<br \/>\n\u2705 Op\u021biune de medicament oral<\/p>\n<p><strong>Ezedoc<\/strong> con\u021bine <strong>Ezetimibe<\/strong>.<\/p>","protected":false},"featured_media":56973,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3953],"product_tag":[4210,4211],"class_list":{"0":"post-56972","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-high-cholesterol-treatments","9":"product_tag-ezedoc","10":"product_tag-ezetimibe","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/56972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=56972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/56973"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=56972"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=56972"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=56972"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=56972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}